AnaptysBio, Inc. (ANAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$56.80-1.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANAB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | 232.4 | 234.6 | 91.3 | 17.2 | 10.3 | 63.2 | 75.0 | 8.0 | 5.0 | 10.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 10.0 |
| Operating Expenses & Income | ||||||||||
| R&D Expenses | — | — | — | — | 88.8 | 98.5 | 80.0 | 99.3 | 56.2 | 29.4 |
| Operating Income | 40.8 | 47.9 | (114.9) | (164.4) | (115.2) | (56.8) | (23.9) | (107.4) | (66.7) | (28.8) |
| Earnings from Continuing Operations | ||||||||||
| Interest Expense | — | — | — | — | — | 0.0 | 0.0 | 1.0 | 1.7 | 1.8 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | 1.6 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | 0.2 |
| Other Non-Operating Income / Expenses | (67.4) | (61.0) | (30.3) | 0.8 | (13.5) | (1.0) | 3.9 | 9.9 | 4.9 | (1.3) |
| EBT, Incl. Unusual Items | (26.6) | (13.1) | (145.2) | (163.6) | (128.7) | (57.8) | (19.9) | (97.5) | (61.8) | (30.1) |
| Income Tax Expense | — | 0.2 | 0.0 | (0.0) | 0.0 | 0.0 | 0.0 | (0.2) | (0.2) | 0.0 |
| Net Income | ||||||||||
| Net Income | (26.8) | (13.2) | (145.2) | (163.6) | (128.7) | (57.8) | (19.9) | (97.3) | (61.7) | (30.1) |
| Per Share | ||||||||||
| Basic EPS | (0.93) | (0.46) | (5.12) | (6.08) | (4.57) | (2.11) | (0.73) | (3.60) | (2.50) | (1.52) |
| Diluted EPS | (0.93) | (0.46) | (5.12) | (6.08) | (4.57) | (2.11) | (0.73) | (3.60) | (2.50) | (1.52) |
| Revenue per Share | 8.10 | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 28.7 | 28.8 | 28.4 | 26.9 | 28.2 | 27.4 | 27.3 | — | — | — |
| Diluted Weighted Avg Shares | 28.7 | 28.8 | 28.4 | 26.9 | 28.2 | 27.4 | 27.3 | — | — | — |
| Supplemental | ||||||||||
| EBITDA | — | 48.5 | (114.3) | (163.8) | (114.5) | (56.2) | (23.3) | (106.9) | (66.4) | (28.6) |
| EBIT | 40.8 | 47.9 | (114.9) | (164.4) | (115.2) | (56.8) | (23.9) | (107.4) | (66.7) | (28.8) |
| Effective Tax Rate | — | — | — | 0.0% | -0.0% | 0.0% | 0.0% | 0.2% | 0.3% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.